Clinical Trials Browser

Phase NA × Refractory Solid Tumors × Sunitinib × Clear all

NCT02450123 2022-06-15

Single-arm Study to Evaluate the Safety and Efficacy of Sunitinib, in Subjects With RET Fusion Positive or FGFR2 Amplification, Refractory Solid Tumors

Phase NA Completed

Other solid neoplasm

Refractory Solid Tumors